150 related articles for article (PubMed ID: 33999445)
1. TRAF3 and NBR1 both influence the effect of the disease-causing CYLD(Arg936X) mutation on NF-κB activity.
Danis J; Kelemen E; Rajan N; Nagy N; Széll M; Ádám É
Exp Dermatol; 2021 Nov; 30(11):1705-1710. PubMed ID: 33999445
[TBL] [Abstract][Full Text] [Related]
2. Identification of putative phenotype-modifying genetic factors associated with phenotypic diversity in Brooke-Spiegler syndrome.
Pap ÉM; Farkas K; Széll M; Németh G; Rajan N; Nagy N
Exp Dermatol; 2020 Oct; 29(10):1017-1020. PubMed ID: 32744342
[TBL] [Abstract][Full Text] [Related]
3. A novel missense mutation of the CYLD gene identified in a Hungarian family with Brooke-Spiegler syndrome.
Nagy N; Farkas K; Kinyo A; Nemeth IB; Kis E; Varga J; Bata-Csorgo Z; Kemeny L; Szell M
Exp Dermatol; 2012 Dec; 21(12):967-9. PubMed ID: 23171463
[TBL] [Abstract][Full Text] [Related]
4. A novel large deletion of the CYLD gene causes CYLD cutaneous syndrome in a Chinese family.
Zhu R; Xu J; Shen J; Li W; Tan F; Li C; Wei Z; Liu Y; Bai Y
Mol Genet Genomic Med; 2020 Oct; 8(10):e1441. PubMed ID: 32783365
[TBL] [Abstract][Full Text] [Related]
5. Brooke-Spiegler syndrome: report of two cases not associated with a mutation in the CYLD and PTCH tumor-suppressor genes.
Ponti G; Nasti S; Losi L; Pastorino L; Pollio A; Benassi L; Giudice S; Bertazzoni G; Veratti E; Azzoni P; Bianchi Scarrà G; Seidenari S
J Cutan Pathol; 2012 Mar; 39(3):366-71. PubMed ID: 22077640
[TBL] [Abstract][Full Text] [Related]
6. A case of Brooke-Spiegler syndrome with a novel mutation in the CYLD gene in a patient with aggressive non-Hodgkin's lymphoma.
Hunstig F; Schulz S; Nieten I; Froster U; Boltze C; Schliemann S; Hochhaus A; La Rosée P
J Cancer Res Clin Oncol; 2016 Apr; 142(4):845-8. PubMed ID: 26660106
[TBL] [Abstract][Full Text] [Related]
7. Large germline deletions of the CYLD gene in patients with Brooke-Spiegler syndrome and multiple familial trichoepithelioma.
Vanecek T; Halbhuber Z; Kacerovska D; Martinek P; Sedivcova M; Carr RA; Slouka D; Michal M; Kazakov DV
Am J Dermatopathol; 2014 Nov; 36(11):868-74. PubMed ID: 25347032
[TBL] [Abstract][Full Text] [Related]
8. CYLD mutations differentially affect splicing and mRNA decay in Brooke-Spiegler syndrome.
Parren LJMT; Baron JM; Joussen S; Marquardt Y; Hanneken S; van Steensel MAM; Steijlen PM; van Geel M; Frank J
J Eur Acad Dermatol Venereol; 2018 Aug; 32(8):e331-e333. PubMed ID: 29478249
[No Abstract] [Full Text] [Related]
9. Phenotype variability in tumor disorders of the skin appendages associated with mutations in the CYLD gene.
Parren LJMT; Giehl K; van Geel M; Frank J
Arch Dermatol Res; 2018 Sep; 310(7):599-606. PubMed ID: 29974194
[TBL] [Abstract][Full Text] [Related]
10. Clinical, genetic and experimental studies of the Brooke-Spiegler (CYLD) skin tumor syndrome.
Andersson MK; Kölby L; Nilsson JA; Stenman G
J Plast Surg Hand Surg; 2019 Apr; 53(2):71-75. PubMed ID: 30676842
[TBL] [Abstract][Full Text] [Related]
11. Novel and recurrent germline and somatic mutations in a cohort of 67 patients from 48 families with Brooke-Spiegler syndrome including the phenotypic variant of multiple familial trichoepitheliomas and correlation with the histopathologic findings in 379 biopsy specimens.
Grossmann P; Vanecek T; Steiner P; Kacerovska D; Spagnolo DV; Cribier B; Rose C; Vazmitel M; Carlson JA; Emberger M; Martinek P; Pearce RL; Pearn J; Michal M; Kazakov DV
Am J Dermatopathol; 2013 Feb; 35(1):34-44. PubMed ID: 23249834
[TBL] [Abstract][Full Text] [Related]
12. The CYLD p.R758X worldwide recurrent nonsense mutation detected in patients with multiple familial trichoepithelioma type 1, Brooke-Spiegler syndrome and familial cylindromatosis represents a mutational hotspot in the gene.
Farkas K; Deák BK; Sánchez LC; Martínez AM; Corell JJ; Botella AM; Benito GM; López RR; Vanecek T; Kazakov DV; Kromosoeto JN; van den Ouweland AM; Varga J; Széll M; Nagy N
BMC Genet; 2016 Feb; 17():36. PubMed ID: 26861065
[TBL] [Abstract][Full Text] [Related]
13. NF-κB over-activation portends improved outcomes in HPV-associated head and neck cancer.
Schrank TP; Prince AC; Sathe T; Wang X; Liu X; Alzhanov DT; Burtness B; Baldwin AS; Yarbrough WG; Issaeva N
Oncotarget; 2022; 13():707-722. PubMed ID: 35634245
[TBL] [Abstract][Full Text] [Related]
14. Phenotype-genotype correlations for clinical variants caused by CYLD mutations.
Nagy N; Farkas K; Kemény L; Széll M
Eur J Med Genet; 2015 May; 58(5):271-8. PubMed ID: 25782638
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic modifiers DNMT3A and BCOR are recurrently mutated in CYLD cutaneous syndrome.
Davies HR; Hodgson K; Schwalbe E; Coxhead J; Sinclair N; Zou X; Cockell S; Husain A; Nik-Zainal S; Rajan N
Nat Commun; 2019 Oct; 10(1):4717. PubMed ID: 31624251
[TBL] [Abstract][Full Text] [Related]
16. Multiple (familial) trichoepitheliomas: a clinicopathological and molecular biological study, including CYLD and PTCH gene analysis, of a series of 16 patients.
Kazakov DV; Vanecek T; Zelger B; Carlson JA; Spagnolo DV; Schaller J; Nemcova J; Kacerovska D; Vazmitel M; Sangüeza M; Emberger M; Belousova I; Fernandez-Figueras MT; Kempf W; Meyer DR; Rütten A; Baltaci M; Michal M
Am J Dermatopathol; 2011 May; 33(3):251-65. PubMed ID: 21389835
[TBL] [Abstract][Full Text] [Related]
17. A new Cylindromatosis (CYLD) gene mutation in a case of Brooke-Spiegler syndrome masquerading as basal cell carcinoma of the eyelids.
Hester CC; Moscato EE; Kazakov DV; Vanecek T; Moretto JC; Seiff SR
Ophthalmic Plast Reconstr Surg; 2013; 29(1):e10-1. PubMed ID: 22689134
[TBL] [Abstract][Full Text] [Related]
18. Diverse presentations of cutaneous mosaicism occur in CYLD cutaneous syndrome and may result in parent-to-child transmission.
Arefi M; Wilson V; Muthiah S; Zwolinski S; Bajwa D; Brennan P; Blasdale K; Bourn D; Burn J; Santibanez-Koref M; Rajan N
J Am Acad Dermatol; 2019 Dec; 81(6):1300-1307. PubMed ID: 31085270
[TBL] [Abstract][Full Text] [Related]
19. Cylindromatosis (Cyld) gene mutation in T cells promotes the development of an IL-9-dependent allergic phenotype in experimental asthma.
Reuter S; Maxeiner J; Meyer-Martin H; Michel A; Baars P; Bopp T; Waisman A; Reissig S; Wehler TC; Schild H; Taube C; Stassen M; Becker M
Cell Immunol; 2016 Oct; 308():27-34. PubMed ID: 27372382
[TBL] [Abstract][Full Text] [Related]
20. Tropomyosin Receptor Antagonism in Cylindromatosis (TRAC), an early phase trial of a topical tropomyosin kinase inhibitor as a treatment for inherited CYLD defective skin tumours: study protocol for a randomised controlled trial.
Cranston A; Stocken DD; Stamp E; Roblin D; Hamlin J; Langtry J; Plummer R; Ashworth A; Burn J; Rajan N
Trials; 2017 Mar; 18(1):111. PubMed ID: 28270164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
